Wednesday, August 4, 2021

Axios Vitals: NYC revives vaccine passports

Plus, Humira's biosimilars blockade | Wednesday, August 04, 2021
 
Axios Open in app View in browser
 
Presented By Partnership for America's Health Care Future
 
Axios Vitals
By Tina Reed ·Aug 04, 2021

Good morning, Vitals readers. Today's newsletter is 897 words, or a 3-minute read.

💉 Situational awareness: The FDA is aiming to complete the process of fully approving the Pfizer-BioNTech coronavirus vaccine by the start of next month, New York Times reported.

 
 
1 big thing: New York City revives vaccine passports
An illustration of the Statue of Liberty with vaccines coming out of her crown.

Illustration: Aïda Amer/Axios

 

New York City's move to become the first city in the U.S. to require proof of a COVID vaccine for indoor dining is bringing back the idea of vaccine passports, Axios' Caitlin Owens writes.

Why it matters: "Immunity passports" have so far gotten a lot more hype than actual attention — but now employers and local governments want to ensure that remaining unvaccinated will have consequences for everyday life.

Driving the news: New Yorkers will soon have to prove they are fully vaccinated to dine indoors, visit gyms or participate in other indoor entertainment.

  • Some restaurants voluntarily adopted such policies already, but New York has become the first government to mandate them.
  • Denver recently announced that it will require city employees and private-sector workers in "high-risk settings" to be vaccinated, and New Jersey is also requiring some of the state's frontline workers to be vaccinated.
  • Employer vaccine mandates have continued to spread like wildfire. Tyson Foods notably announced yesterday that it will require its workers to be vaccinated, even though around half of them currently are not, per NYT.

Between the lines: Dropping the push for an easy digital vaccine verification system may look like a bad idea in retrospect.

  • For now, most Americans' only proof of vaccination, should they need it, is their paper CDC card.

Yes, but: Employer vaccine mandates and vaccine passports, if they catch on, will eventually run into a red wall.

  • Many GOP-led states preemptively put limitations on vaccine requirements and the use of vaccine passports.
  • It's unclear whether any other governments will follow New York City's lead. President Biden said yesterday that he thinks they should.

Share this story.

Share on Facebook Tweet this Story Post to LinkedIn Email this Story
 
 
2. Most Americans fear for the future...
Data: Harris Poll; Chart: Axios Visuals

America took a brief hiatus from worrying about the pandemic, but the Delta variant and the response to it appear to have sent the U.S. back to a dark place, Caitlin writes.

  • New Harris polling provided exclusively to Axios shows a majority of Americans now, once again, say the worst of the pandemic is yet to come.
Share on Facebook Tweet this Story Post to LinkedIn Email this Story
 
 
3. ...while the unvaccinated fear the jab
Data: KFF COVID-19 Vaccine Monitor; Chart: Will Chase/Axios

Nearly one in four Americans are more concerned about the risks of the COVID-19 vaccine than the virus itself, according to the latest installment of the KFF Vaccine Monitor.

Driving the news: At least 22% of respondents said they were more concerned about the shot than the virus. Among the unvaccinated, that rate rose to 53%.

  • Three in four unvaccinated adults said they are "not worried" about getting seriously sick from the virus; less than half said they are worried about the Delta variant; and less than a quarter believe the vaccines are effective at protecting against death or serious illness.

What they're saying: "It will be interesting to see as more cities and states and places require vaccines whether that will change the behaviors, not because they think the pandemic is bad or are worried about getting sick, but because they are required to," Ashley Kirzinger, KFF's associate director of public opinion and survey research, told Axios.

Share on Facebook Tweet this Story Post to LinkedIn Email this Story
 
 

A message from Partnership for America's Health Care Future

Let's build on what's working, not threaten access to care
 
 
As some politicians explore creating a new government-controlled health insurance system, research finds the public option could force hospitals to reduce critical services – disproportionately harming underserved communities. See the findings.
 
 
4. Long COVID is rare in kids

Long-term symptoms from COVID are rare in kids, according to a study published yesterday in the journal The Lancet Child & Adolescent Health.

Why it matters: As parents prepare to send their children back to school without the protection of a vaccine, severe long-term impacts of COVID remain a primary concern.

Researchers examined 1,734 cases of symptomatic COVID-19 in kids in the U.K. and found they typically recovered within six days.

  • Fewer than 5% of kids experienced symptoms beyond four weeks.
  • For kids who did experience symptoms longer than a month, the most common persistent symptom was fatigue (84%), followed by loss of sense of smell. Headaches were also among the most common persistent symptoms but were more common early in the illness.
  • Almost all kids (98.2%) with symptomatic illness recovered from their symptoms within eight weeks.

Zoom out: Teens were typically sick longer — for about seven days — than kids younger than 12 who were sick about five days on average.

  • Older kids were also more likely to have symptoms after a month (5.1%) compared to kids ages 3 to 12 (3.1%).
Share on Facebook Tweet this Story Post to LinkedIn Email this Story
 
 
5. AbbVie's biosimilar blockade
Data: Company filings; Chart: Axios Visuals

Sales of Abbvie's blockbuster anti-inflammatory drug Humira have declined internationally, as cheaper copycats known as biosimilars gain more traction in Europe.

Why it matters: Humira sales continued to rise in the U.S. last quarter because Humira biosimilars are locked out of the country until 2023, Axios Bob Herman writes.

Cheaper versions of Humira exist, but Americans don't have access to them due to legal settlements that delay entry.

  • Humira biosimilars entered the European market in October 2018.
  • AbbVie signed deals with biosimilar manufacturers that prevent those biosimilars from entering the U.S. market until 2023.

Share this story.

Share on Facebook Tweet this Story Post to LinkedIn Email this Story
 
 
6. The Simone Biles effect on mental health
Data: NewsWhip; Chart: Axios Visuals

Simone Biles' withdrawal from Olympics gymnastics events generated significant public interest in mental health, Axios' Neal Rothschild writes, based on exclusive data from NewsWhip.

Why it matters: Biles sparked a bigger conversation about mental health than either Prince Harry and Meghan Markle's interview with Oprah or Naomi Osaka's withdrawal from the French Open.

  • Google searches about mental health spiked the day she withdrew, hitting their highest level in more than two months.

The spotlight from Biles could help bolster attention for mental health services, which saw a massive surge in demand during the pandemic, as well as stark examples of disparities in access to care.

Share on Facebook Tweet this Story Post to LinkedIn Email this Story
 
 

A message from Partnership for America's Health Care Future

Let's build on what's working, not threaten access to care
 
 
Americans need lawmakers to build on and improve what's working in health care, not start over by creating a new government-controlled health insurance system like the public option that could threaten access to care for racial and ethnic minorities and rural Americans. Learn more.
 
HQ
Like this email style and format? Learn more about Axios HQ.
It'll help you deliver employee communications more effectively.
 

Axios thanks our partners for supporting our newsletters. If you're interested in advertising, learn more here.
Sponsorship has no influence on editorial content.

Axios, 3100 Clarendon B‌lvd, Suite 1300, Arlington VA 22201
 
You received this email because you signed up for newsletters from Axios.
Change your preferences or unsubscribe here.
 
Was this email forwarded to you?
Sign up now to get Axios in your inbox.
 

Follow Axios on social media:

Axios on Facebook Axios on Twitter Axios on Instagram
 
 
                                             

No comments:

Post a Comment

J.P. Morgan preparing for market meltdown?

Why is J.P. Morgan stockpiling silver? ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ...